Bausch + Lomb, the global eye health company, today announced that it is has received approval from the U.S. Food and Drug Administration (FDA) for the TRULIGN™ Toric posterior chamber intraocular lens (IOL).  The TRULIGN Toric intraocular lens is the first toric IOL that corrects for astigmatism and, unlike other standard toric lenses, has the additional capacity to deliver improved vision across a natural range of focus. The lens is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia and postoperative refractive astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia who desire reduction of residual refractive cylinder with increased spectacle independence and improved uncorrected near, intermediate and distance vision.